National HealthCare Corporation (NHC) Stock Forecasts

NATIONAL HEALTHCARE CORP (NHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 For release: August 7, 2026 Contact: Brian F. Kidd, SVP/CFO Phone: (615) 890-2020 NHC Reports Second Quarter 2026 Earnings MURFREESBORO, Tenn. -- National HealthCare Corporation (NYSE American: NHC), the nation's oldest publicly traded senior health care company, ann

NATIONAL HEALTHCARE CORP (NHC) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.2 3 ex_983366.htm EXHIBIT 10.2 ex_983366.htm Exhibit 10.2 PARTIAL MASTER LEASE TERMINATION AGREEMENT AND PARTIAL ASSIGNMENT AND ASSUMPTION OF MASTER LEASE This Partial Master Lease Termination Agreement and Partial Assignment and Assumption of Master Lease (this “ Agreement

Australian coal stocks rose sharply after a deadly explosion at China’s Liushenyu mine in Shanxi raised concerns about tighter coking coal supply. Whitehaven Coal gained 8.7%, Yancoal 7.5% and New Hope 4.7%, outpacing the ASX 200, as Chinese coking coal futures jumped nearly 8% to their limit. The accident killed at least 82 miners, and China ordered a safety investigation.

Galp Energia and Equinor have been awarded an offshore oil block in Brazil's Santos Basin. Galp will own 30% of the Rodocrosita block, with Equinor operating the remaining 70%. The companies may explore synergies with the adjacent Bacalhau project, which is ramping up production and will contribute 40,000 barrels per day to Galp once fully operational.

Pinterest (PINS) appointed Amazon's James Dibbo as its new CFO. The company's stock has shown mixed performance, with a recent 7-day return of 7.52% but a 1-year return of -36.11%. Analysts have varying views on its valuation, with some seeing it as undervalued at $20.31 per share compared to a fair value estimate of $29.05, while others note its high P/E ratio of 46.2x.

Shanghai Allist Pharmaceuticals (SS:688578) shares dropped 20% after its U.S. partner ArriVent Biopharma (NASDAQ:AVBP) reported that a late-stage trial of lung cancer drug firmonertinib failed to meet its primary endpoint. The drug did not show a statistically significant improvement in progression-free survival for patients with non-small cell lung cancer.